Life Sciences

  • October 07, 2026

    JPML Consolidates Nevro, Abbott Spinal Cord Device Suits

    The Judicial Panel on Multidistrict Litigation has created separate MDLs over purportedly defective spinal cord stimulators manufactured by Nevro LLC and Abbott Laboratories, rejecting the manufacturers' arguments that the cases' plaintiffs do not share enough common factual questions to warrant consolidation.

  • October 07, 2026

    Ark. Panel Says Insurers Must Defend Walmart Opioid Suits

    Insurers for Walmart must defend the retail giant against underlying suits claiming its sale of prescription painkillers contributed to the opioid epidemic, an Arkansas state appeals court affirmed Wednesday, finding that the suits allege accidental conduct and are seeking damages because of bodily injury.

  • October 07, 2026

    Zoetis Says Horse Owners Must Abide Deal To End Death Suit

    Zoetis Inc. on Wednesday asked a Pennsylvania federal court to enforce a confidential settlement with the owners of a 3-year-old racehorse that they alleged died after receiving one of Zoetis' antibiotics, saying the plaintiffs can't ignore the agreement and their own counsel.

  • October 07, 2026

    Fed. Circ. Won't Rehear Axed $49M Verdict In Stent Fight

    The Federal Circuit on Wednesday denied a bid from the University of Texas to get a panel to rehear its patent infringement case where a $49.4 million jury verdict against Boston Scientific was overturned.

  • October 07, 2026

    PhRMA Sues To Block Medicare Foreign Drug Price Rule

    The pharmaceutical industry's top lobbying group asked a D.C. federal judge Wednesday to block a new Medicare rule tying Part B drug payments to prices abroad, claiming that the U.S. Department of Health and Human Services is imposing a "most-favored-nation" price control that Congress has repeatedly declined to enact.

  • October 07, 2026

    3rd Circ. Upends Sandoz's $61.6M Award Against UTC

    A Third Circuit panel on Wednesday erased Sandoz Inc.'s $61.6 million award in a breach of contract case against United Therapeutics Corp., in a decision that sidesteps the major pharmaceutical company's request to reinstate a $137.2 million damages calculation that had been halved by the trial judge.

  • October 07, 2026

    Vape Group, Makers Want In On FDA E-Cig Enforcement Suit

    A vape industry group and a pair of manufacturers are asking a Maryland federal court to let them intervene on the side of the federal government in a suit by health groups challenging new guidance on enforcement priorities for new tobacco products.

  • October 07, 2026

    Remorseful Atty Says He'll Skip Solo Practice If Reinstated

    A suspended Uniontown, Pennsylvania, attorney told a disciplinary panel Wednesday that he would avoid solo practice and focus on regulatory compliance work for a clinical trial company if reinstated, citing regret for the lack of supervision, burnout and drug abuse that led to his 2025 suspension.

  • October 07, 2026

    Immunomedics Founder Says Deal Triggered $365M Pay Claim

    The founder of Immunomedics urged Delaware's highest court Wednesday to reinstate his roughly $365 million compensation claim against the biotechnology company, alleging Gilead Sciences Inc. became an "affiliate" when it bought Immunomedics for $21 billion and that his employment agreement therefore reaches Gilead's revenues.

  • October 07, 2026

    Kirkland-Led Sheridan Secures $1.345B For 2 Latest Funds

    Kirkland & Ellis LLP-advised Sheridan Capital Partners on Wednesday revealed that it raised $1.345 billion across two new funds, which will be used to invest across various healthcare sectors.

  • October 07, 2026

    Commerce Finalizes Indian, Turkish Chromium Duty Rates

    The U.S. Department of Commerce finalized duty rates for a compound used primarily in wood preservation, metal finishing and plating imported from India and Turkey, according to notices published Wednesday. 

  • October 06, 2026

    AstraZeneca Takes Drug-Pricing Law Challenge To 4th Circ.

    AstraZeneca on Monday asked the Fourth Circuit to resurrect its suit challenging how the Centers for Medicare & Medicaid Services determines which drugs are subject to the landmark drug-pricing program, arguing that CMS is dodging limits on how many drugs can be selected by grouping some together.

  • October 06, 2026

    CVS Can't Get Second Shot At Tossing Investors' AI Use Suit

    A New York federal judge on Tuesday declined to give CVS another opportunity to dismiss a lawsuit accusing it of inflating its revenues through the use of artificial intelligence. 

  • October 06, 2026

    Roundup Expert Admits EPA Clear On Overall Lack Of Harm

    A toxicologist testifying in the latest Roundup trial acknowledged Tuesday that the U.S. Environmental Protection Agency's exhaustive 2017 review of glyphosate science found that the balance of the evidence didn't support a link between glyphosate and human cancer.

  • October 06, 2026

    NC Biz Court Bulletin: Monopoly Suit Setback, Historic Deal

    The North Carolina Business Court rounded the corner into fall with a setback for residents in an antitrust class action, a historic settlement in "forever chemical" contamination litigation and a raft of new restrictive covenant complaints.

  • October 06, 2026

    1st Circ. Sees Gaps In Order Halting RFK's Vaccine Advisers

    A First Circuit panel on Tuesday puzzled over aspects of a lower court's order staying Health and Human Services Secretary Robert F. Kennedy Jr.'s appointments to a vaccine policy committee, with one judge saying he can't tell what authority the order was based on.

  • October 06, 2026

    Anthem BCBS Accused Of Failing To Reimburse 7 Hospitals

    Anthem Blue Cross and Blue Shield is facing claims in Georgia federal court filed by acute care hospitals in six states alleging the insurer failed to cover claims at agreed-upon rates and denied claims for reasons not allowed by their contracts.

  • October 06, 2026

    FDA Accuses 10 Retailers Of Selling Unapproved STI Meds

    Federal regulators have accused Amazon, Walmart and other online retailers of selling unapproved drugs to treat herpes and other sexually transmitted infections, according to warning letters disclosed to the public Tuesday.

  • October 06, 2026

    Texas Justices To Review Law Firms' Paxil Fees Fight

    The Texas Supreme Court has agreed to wade into a battle between two law firms over fees generated from litigation involving the antidepressant Paxil, with the dispute centering on application of the personal injury exemption in the state's anti-SLAPP statute.

  • October 06, 2026

    4 Firms Advise On $5.8B Option Care Health Take-Private Deal

    Private equity firm Clayton Dubilier & Rice and healthcare company McKesson Corp. said Tuesday they have agreed to acquire Option Care Health for $5.8 billion, taking the largest U.S. independent provider of home and alternate-site infusion services private.

  • October 06, 2026

    7th Circ. Judge Hints Precedent Dooms Worker's Vax Fight

    A Seventh Circuit judge appeared disinclined Tuesday to restart a religious discrimination suit brought by a hospital pharmacy technician who was fired for refusing to get the COVID-19 vaccine, emphasizing that the same employer's recent win in a similar appeal is "binding authority."

  • October 06, 2026

    Pharma Sales Rep. Says Taking Cancer Leave Got Him Fired

    A former sales representative has filed a disability bias suit against a pharmaceutical company in Georgia federal court, claiming he was unlawfully fired after a kidney cancer diagnosis made him take leave and delayed a product launch.

  • October 05, 2026

    Roundup Evidence Strong In Every Research Area, Jury Hears

    A jury weighing cancer claims against Monsanto heard testimony Monday that scientific research shows a "strong" link between glyphosate and cancer in animal, molecular and human epidemiological studies, even when accounting for participants' exposure to other substances.

  • October 05, 2026

    Verogen Genealogy Website Can't Escape DNA Privacy Suit

    A California federal judge has preserved a proposed class action against the owner-operator of a genetic genealogy website, finding that the plaintiffs sufficiently showed that a technical loophole wrongly let law enforcement circumvent user opt-out privacy settings.

  • October 05, 2026

    Masimo's $634M Apple IP Win Boosted By $184M In Interest

    A California federal judge on Monday ordered Apple Inc. to pay Masimo Corp. $184 million in prejudgment interest on top of a $634 million damages award for infringing a Masimo pulse oximetry patent through an Apple Watch feature, rejecting Apple's contention that such interest was not warranted.

Expert Analysis

  • Justices' Hikma Reasoning May Extend Well Beyond Pharma

    Author Photo

    The active steps framework announced by the U.S. Supreme Court in its Hikma v. Amarin decision, finding that Amarin failed to plausibly allege inducement of infringement, has the potential to reshape how courts evaluate inducement claims across patent, copyright and other doctrines, say attorneys at BCLP.

  • Teva MDL Loss Shows DPAs Can Return To Haunt Civil Suits

    Author Photo

    Teva’s recent partial summary judgment loss in antitrust multidistrict litigation reinforces the importance of carefully scrutinizing any statement of facts a company admits to in a deferred prosecution agreement, and illustrates the potential costs of resolving a criminal investigation this way, say attorneys at Sheppard.

  • An Inside Look At Squires' Discretionary Denials

    Author Photo

    A deep dive into the discretionary denials issued by U.S. Patent and Trademark Office Director John Squires since he took over last year identifies trends in commonly asserted arguments and how they correlate with institution outcomes, say attorneys at Kirkland & Ellis.

  • Series

    Ballet Makes Me A Better Lawyer

    Author Photo

    A lifetime of learning and performing ballet taught me that success — whether in dance or practicing law — comes only through hours of thorough preparation, boundless energy and relentless effort, says Sharon Katz-Pearlman at Greenberg Traurig.

  • Fed. Circ. In July: Meeting The Enablement Requirement

    Author Photo

    The Federal Circuit's decision in Wyeth v. AstraZeneca last month exemplifies when a generalized conception of an invention is insufficient to enable the full scope of asserted patent infringement claims, and may lead to more enablement challenges, say attorneys at Knobbe Martens.

  • Series

    Taekwondo Makes Me A Better Lawyer

    Author Photo

    Taekwondo has taught me to recognize when to fight for a position and when to focus on finding a solution, and that the best outcomes are often achieved by solving problems — all of which has improved my work as a bankruptcy lawyer, mediator and Subchapter V trustee, says Amy Denton Mayer at Berger Singerman.

  • Why AI Diligence Is Especially Key In IP Practice

    Author Photo

    In light of recent federal court sanctions against intellectual property litigators for filing work product generated by artificial intelligence without verification, it's important to consider the unique risks and consequences that can arise from overreliance on AI, which poses less visible risks in IP matters, says Stephen Ball at Husch Blackwell.

  • How 'Most Favored Nation' Regime Affects Biopharma Deals

    Author Photo

    As M&A activity surges in the biopharma space, companies will need to account for the Trump administration's most-favored-nation pricing proposals — durable in concept, if unsettled in detail — when drafting deals, say attorneys at Gibson Dunn.

  • What To Know As Legal Duty To Consider AI Takes Shape

    Author Photo

    While the U.K. Jurisdiction Taskforce’s recent statement on liability for artificial intelligence harms is nonbinding for both U.K. and U.S. lawyers, it highlights the importance of being able to distinguish between the availability of a tool and a professional obligation to use it, say Jonny Frank and Michael Costa at StoneTurn.

  • NC Dental Review Change Counters Tougher National Trend

    Author Photo

    North Carolina’s elimination of its prior review requirement for dental management agreements departs sharply from the national trend toward expanded corporate practice of medicine oversight, but stakeholders should not view this regulatory shift as a relaxation of compliance expectations, say attorneys at Holland & Knight.

  • NY Bill Would Boost Litigation Risk For Cosmetics Cos.

    Author Photo

    The Beauty Justice Act, now pending in the New York Legislature, would not only present compliance challenges for companies making cosmetics and personal care products, but could also be used by private plaintiffs to bring consumer fraud, false advertising, toxic exposure and product liability claims, says Kadeejah Kelly-Previl at Faegre Drinker.

  • How To Structure Protective Order AI Provisions In IP Disputes

    Author Photo

    A survey of protective orders in recent intellectual property litigation reveals best practices for drafting provisions on artificial intelligence use that maximize IP protection while balancing enforceability with efficient discovery, say Matthew Stephens and Bryce Tabbut at MoFo.

  • Appellate Vape Rulings May Expand State Regulation Powers

    Author Photo

    Two recent federal appeals courts decisions rejecting Federal Food, Drug and Cosmetic Act preemption challenges to state electronic nicotine delivery systems directory laws signal an emerging appellate consensus that could significantly expand states' power to regulate vaping product sales where federal enforcement falls short, say attorneys at Troutman.

  • 5 Lessons For VC Investors From Del. IPO Ruling

    Author Photo

    The Delaware Court of Chancery's recent dismissal of Rostov v. Alcon Research, a derivative action over a proposed initial public offering, provides multiple practice pointers for venture capital investors, including the importance of precisely worded corporate documents and pleading a coherent theory of corporate harm, says Ben Dubin at VC Expert Services.

  • Fed. Circ. Rulings Emphasize Adjudicative Access And Review

    Author Photo

    Decisions from the Federal Circuit's 2026 docket indicate that the court is increasingly paying attention to whether tribunals possess authority to act, meaning practitioners will need to properly address procedural hurdles before they can argue the merits of a case, say attorneys at Reichman Jorgensen.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.